US EditionPublished • loading... • Updated
Mytos Launches Automated CDMO for Manufacturing Stem-Cell Derived Therapies
Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative medicine’s greatest bottlenecks: scalable, affordable manufacturing of stem cell-derived therapies. The first facility, housed within the Cell and Gene Therapy Catapult’s (CGT Catapult) Stevenage Manufacturing Innovation Centre, is targeting clinical…
1 Articles
1 Articles
Mytos Launches Automated CDMO for Manufacturing Stem-Cell Derived Therapies
Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative medicine’s greatest bottlenecks: scalable, affordable manufacturing of stem cell-derived therapies. The first facility, housed within the Cell and Gene Therapy Catapult’s (CGT Catapult) Stevenage Manufacturing Innovation Centre, is targeting clinical…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
